Cibus Stock

cibus.comHealthcare / BioTech & PharmaFounded: 2001Funding to Date: $183.76MM

Developer of a plant and microbial breeding platform intended to advance in non-transgenic breeding technologies. The company's platform uses proprietary and highly differentiated non-transgenic gene-editing technologies to offer site-specific edits of native genes with no introduction of foreign DNA, enabling biologists to avail non-transgenic traits for most major crops.

Register To Buy and Sell Shares

For more details on financing and valuation for Cibus, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Cibus’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cibus.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Peter Beetham Ph.D
Founder, President, Board Member & Chief Executive Officer
James Hinrichs
Chief Financial Officer
Greg Gocal Ph.D
Co-Founder, Chief Scientific Officer & Executive Vice President
Jonathan Wygant
Chief Accounting Officer
David Songstad Ph.D
Director of Research and Cell Biology
Kay Kuenker
Executive Vice President, Strategy
Rory Riggs
Co-Founder & Chairman
Keith Walker Ph.D
Co-Founder & Board Member

Board Members

Eugene Linden
Alain Pompidou
Gerhard Prante Ph.D
Keith Walker Ph.D
Mark Finn
Richard Spizzirri Ph.D
Peter Beetham Ph.D
Rory Riggs
Christopher Richards Ph.D
Jean-Pierre Lehmann
Mark Lu

Frequently Asked Questions About Cibus’ Stock

plusminus
Can you buy Cibus’ stock?
Cibus is not publicly traded on NYSE or NASDAQ in the U.S. To buy Cibus’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Cibus’ stock?
Yes, you can sell stock of a private company like Cibus. Forge can help you sell your Cibus stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Cibus’ stock price?
Cibus is a privately held company and therefore does not have a public stock price. However, you may access Cibus’ private market stock price with Forge Data.
plusminus
What is Cibus’ stock ticker symbol?
Cibus does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Cibus files to go public - PE Hub
San Diego-based Cibus Ltd, a provider of advanced plant-breeding technologies, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Cibus is planning on listing the stock on the NASDAQ under the ticker symbol "CBUS." Morgan Stanley and BofA Merill Lynch are the lead underwriters. The company's backers include Fidelity Management and Research Company, Alexandria Venture Investments and Cormorant Asset Management.
VC-backed Cibus prices IPO - PE Hub
San Diego-based Cibus Ltd, a provider of advanced plant-breeding technologies has priced its IPO of over 6.6 million shares at between $14 and $16 per share. The company plans on trading the stock on the NASDAQ under the ticker symbol "CBUS." Morgan Stanley and BofA Merrill Lynch are the lead underwriters. The company’s backers include Fidelity Management and Research Company, Alexandria Venture Investments and Cormorant Asset Management.
Updated on: May 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.